Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesSafety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization
Bone Marrow Transplantation, 06/24/09
Tricot G et al. - In a trial to assess the safety and efficacy of plerixafor for stem cell mobilization and tumor cell contamination, it was established that the safety profile of plerixafor in all pts was consistent with previous reports.
Methods- This was an open-label, single-center, phase II study of 20 pts with multiple myeloma (MM) who were either proven poor mobilizers (n=10; group A) or predicted poor mobilizers (n=10; group B) and were planned for autologous hematopoietic SCT.
- Peripheral blood (PB) CD34+ cell count was generally very low pre- plerixafor and increased significantly post-plerixafor administration.
- Cumulative apheresis yields of ≥2 x 106 CD34+ cells/kg were observed in 7 of 10 pts (group A) and 8 of 10 pts (group B).
- Among the proven poor mobilizers, there was no evidence of tumor cell mobilization in the PB after G-CSF plus plerixafor treatment.
- 17 of 20 (85%) pts underwent transplantation.
- Neutrophil engraftment occurred at a median of 13 days for all pts.
- Platelet engraftment occurred at a median of 16 days and 19 days for all proven and predicted poor mobilizers, respectively.
- At 12 mos, 12 of 17 pts had documented durable grafts, 3 of 17 pts died and 2 of 17 pts were lost to follow-up; but they had documented graft durability at the previous 3- and 6-mo visit.
Today in BMT/SCT...keeping you current
Receive free subspecialty "5-minute updates" via email
5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis
Bone Marrow Transplantation, 10/15/09
Management of relapse after allo-SCT for AML and the role of second transplantation
Bone Marrow Transplantation, 10/29/09
New advances in the treatment of acute promyelocytic leukemia
International Journal of Hematology, 10/07/09
Today in Leukemia/Lymphoma...keeping you current
Receive free subspecialty "5-minute updates" via email
Lymphoma in patients treated with anti-TNF. Results of the 3-year prospective French RATIO registry.
Annals of Rheumatic Diseases, 10/22/09
Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the childrens oncology group
Journal of Clinical Oncology, 10/12/09
Primary extranodal marginal zone lymphoma of the uvea associated with massive diffuse epibulbar extension and focal infiltration of the optic nerve and meninges, clinically presented as uveitis masquerade syndrome: a case report
Medical Oncology, 10/16/09
Sponsor
Article Search
Sponsor
Sponsor